Pfizer/Ligand’s Osteoporosis Drug Fablyn Gets Advisory Committee Review
This article was originally published in The Pink Sheet Daily
Executive Summary
Lasofoxifene beats out Wyeth’s Viviant for first advisory committee review of the competing next-generation SERMs.